

# Cerulean

**Pharma & biotech**
**20 March 2015**

## Positive data announced for CRLX101 in RCC

In conjunction with its FY14 results, Cerulean announced strong top-line interim data for CRLX101 in its lead indication of relapsed renal cell carcinoma (RCC). The combination treatment with Avastin achieved its primary endpoint of four-month progression free survival (PFS) in at least 50% of patients, showing significant improvement over the current standard of care. Cerulean also confirmed that current cash holdings and recent financing with Hercules provide the company with resources to fund ongoing trials for both CRLX101 and CRLX301 through to Q316.

## CRLX101 Phase Ib/II in RCC solidifies earlier findings

Cerulean provided data from an interim analysis (IA) of its ongoing Phase Ib/II study. Data generated from 22 patients enrolled showed a median progression free survival (PFS) of 9.9 months vs the current standard of care of approximately 3.5 months, and trending upwards from an earlier analysis in the first 11 patients showing PFS of 7.6 months. RECIST (response evaluation criteria in solid tumours) rate was 23% vs the standard of care at just 2-4%. Detailed data from the trial will be presented at ASCO 2015 and submitted for publication in a peer reviewed journal later in the year. Seven patients are still being treated. CRLX101 in combination with Avastin has shown to be well tolerated in this and other studies in more than 250 patients.

## Randomised Phase II trial in RCC underway

CRLX101's potential is significant in relapsed RCC, with an estimated 20-40% of RCC patients experiencing disease recurrence. Existing treatment options are limited. In August 2014 Cerulean initiated a Phase II trial in 3rd- and 4th-line RCC. Up to 110 patients are being enrolled at ~30 centres in the US in the study. This aims to show a 2.3-month improvement in median PFS over the comparator, which is predicted to show 3.5 months PFS. Top-line primary endpoint data and overall response rate data for the Phase II trial are anticipated in Q216.

## Valuation: Potential price inflections on key data

We estimate Cerulean had net cash of ~\$43m at end-February (including a ~\$12m draw-down on its \$26m debt facility), resulting in an EV of ~\$171m; we suggest this is conservative when considering the strong early data, established proof of principle and positive safety profile for its lead drug candidate. Additional trials are underway for CRLX101 plus Avastin in platinum-resistant ovarian cancer (Phase II) and combined with CRT in non-metastatic rectal cancer (Phase Ib/II). A second treatment, CRLX301, is in Phase I in solid tumours. We expect potential share price catalysts related to updated clinical data for each of these trials by year end.

### Consensus forecasts

Year end	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)
12/14	0.1	(23.3)	(1.60)	0.0	N/A	N/A
12/15e	0.0	(44.9)	(2.11)	0.0	N/A	N/A
12/16e	1.0	(57.3)	(2.31)	0.0	N/A	N/A

Source: Bloomberg

**Price \$10.66**
**Market cap \$214m**

### Share price graph



### Share details

Code	CERU
Listing	NASDAQ
Shares in issue	20.1m

### Business description

Cerulean is a US-based oncology-focused company with a differentiated nanoparticle-drug conjugate platform. Lead product CRLX101 combined with Avastin is in Phase II clinical trials in 3rd- and 4th-line RCC and 2nd- and 3rd-line ovarian cancer. CRLX101 in combination with chemoradiotherapy is also in Phase Ib/IIa in neoadjuvant rectal cancer.

### Bull

- Two high-potential products in clinical development.
- Research platform with potential to piggyback off numerous >\$1bn launched oncology products.
- Upcoming clinical catalysts in 2015.

### Bear

- Limited data from larger-scale trials on lead compounds.
- Limited cash reserves to develop full pipeline.
- Company's ability to commercialise products is unproven.

### Analysts

Katherine Genis CFA	+1 (646) 653 7026
Dr Mick Cooper	+44 (0)20 3077 5734

[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority ([www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584](http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584)). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. [www.edisongroup.com](http://www.edisongroup.com)

#### DISCLAIMER

Copyright 2015 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Cerulean and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2015. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.